可切除非小细胞肺癌围术期全程免疫治疗模式的兴起  

The rising of perioperative whole-course immunotherapy for resectable non-small cell lung cancer

作　　者：陈越 刘颖 蔡若雪 郭梦雅 彭炜惟 沙欢欢 方瑛[1] 周国仁[1] CHEN Yue;LIU Ying;CAI Ruoxue;GUO Mengya;PENG Weiwei;SHA Huanhuan;FANG Ying;ZHOU Guoren(Department of Oncology,Jiangsu Cancer Hospital,Nanjing 210009,China)

机构地区：[1]江苏省肿瘤医院内科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2023年第6期591-598,共8页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金项目(82273162)。

摘　　要：肺癌是全世界范围内死亡率最高的癌种,其诊疗进展一直备受关注。其中早中期可手术非小细胞癌(NSCLC)传统上采用以手术为主的综合治疗。随着免疫抑制剂(ICIs)的出现,NSCLC围术期治疗模式也随之改变。愈来愈多的研究表明“全程免疫疗法”可能产生更大获益,即“新辅助化疗联合免疫+手术+免疫单药辅助治疗”,俗称“夹心饼”、“三明治”治疗模式。文章对NSCLC围术期全程免疫疗法的由来及进展进行综述,以期为肺癌围术期综合治疗方案制定提供依据。Lung cancer is the leading cancer in mortality in the world,and its diagnosis and treatment progress have been concerned.In the early and middle stages,operable non-small cell lung cancer(NSCLC)has traditionally been treated with a combination of operations.With the advent of immune checkpoint inhibitors(ICIs),perioperative treatment of NSCLC has also changed.More and more studies have shown that“wholecourse immunotherapy”may produce greater benefits,that is,“neoadjuvant chemotherapy combined with immunotherapy+surgery+immunoadjuvant therapy”,commonly known as“sandwich cake”and“sandwich”treatment mode.This article reviews the origin and progress of perioperative whole-course immunotherapy for NSCLC,in order to provide a basis for the formulation of perioperative comprehensive treatment for lung cancer.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 新辅助治疗 围术期治疗 临床研究 

分 类 号：R734.2[医药卫生—肿瘤]